Novartis News

Novartis announced the availability of PrevacidA 24HR over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn.

Government calls for at-risk individuals to get vaccinated against H1N1 have fallen largely on deaf Swiss ears, with many believing the threat is exaggerated.

SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseases www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.

Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Human Genome Sciences .

For most of us, the very mention of "swine flu" brings about feelings of fear, or at the very least thoughts of fevers, congestion, annoying coughs and stuffy noses.

Novartis announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A 2009 monovalent vaccine, Celtura.

Novartis plans to invest $1 billion during the next 5 years to increase R&D activities in China, including a significant expansion of The Novartis Institute of BioMedical Research in Shanghai.

Roche Holdings AG , maker of the Tamiflu antiviral treatment, is under investigation in South Korea for its alleged involvement in illegal sales of the drug as the number of swine flu cases jumped.

BASEL, Switzerland - Swiss pharmaceutical company Novartis AG said Thursday it has received regulatory approval in Germany for a new swine flu vaccine produced using cell cultures instead of egg-based methods.

Novartis continued its mega-investments in China by announcing it will spend $250 million to expand its global technical center in Changshu, and it will also pay $125 million to buy a 85% stake in a privately held China vaccine company, Zhejiang Tianyuan.

Six projects - from Austria, Germany, Switzerland and the USA - recognized by this year's Novartis Energy Excellence Awards Substantial energy savings and reduction of greenhouse-gas emissions achieved by record number of project submissions Novartis has announced the winners of its annual Energy Excellence Awards , which recognizes associates who ...

Ltd. Privately-held Tianyuan sells vaccines against diseases such as hemorrhagic fever with renal syndrome, or HFRS, caused by hantaviruses, and conducts research into "various preventable viral and bacterial diseases," Novartis said.

Swiss pharmaceutical giant Novartis announced on Tuesday that it would invest 1 billion U.S. dollars in China over the next five years, with a main aim to increase R&D activities in the country.

I last recommended that Fools take a look at consumer-staples company Clorox back in June.

NOVARTIS AG yesterday signed a deal with the Shanghai government to invest an additional US$1 billion over five years in the drug maker's third-biggest research and development center in the world.

Technically, Human Genome Sciences has one drug for sale, but it's between shipments of ABthrax, its anthrax treatment, to the government, so Human Genome's earnings release Thursday was rather dry.

The focus of AstraZeneca 's earnings report illustrates the nature of polar opposites with one-time gains and new drugs.

Human Genome Sciences Inc. narrowed its third-quarter losses by a third, partly by increasing its revenue by 61 percent.

Idenix Pharmaceuticals Inc. says its partner Novartis AG will not move ahead with optioning a license to a potential hepatitis C drug.

Drugmakers say they are on track to deliver as much H1N1 swine flu vaccine to the United States as they promised, despite concerns over production.